Re­silience col­lab­o­rates with the Mayo Clin­ic to man­u­fac­ture rare and com­plex dis­ease drugs

Af­ter net­ting its Se­ries D round of fund­ing in June, Re­silience is not sit­ting around and rest­ing on its lau­rels.

The Bob Nelsen-backed con­tract man­u­fac­tur­er on Mon­day an­nounced a new strate­gic col­lab­o­ra­tion with the Mayo Clin­ic. The re­la­tion­ship is cen­tered around man­u­fac­tur­ing bio­ther­a­peu­tics for rare and com­plex con­di­tions, with the fo­cus on bi­o­log­ics in­clud­ing those based in cells, blood, en­zymes, tis­sues, genes or ge­net­i­cal­ly en­gi­neered cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER